SKN | Scribe Therapeutics Files for $75 Million IPO to Advance CRISPR Gene-Editing Treatments for Cardiovascular Disease
Clinical-Stage Biotech Seeks Nasdaq Listing to Accelerate Next-Generation Gene-Editing Pipeline
Scribe Therapeutics, a clinical-stage biotechnology company developing CRISPR-based therapies for cardiovascular and metabolic diseases, has...
SKN | Londian Wason New Energy Tech Files for Estimated $350 Million US IPO as EV Battery Supply Chain Expands
Chinese Copper Foil Producer Targets NYSE Listing Amid Growing Global Demand for EV Battery Materials
Londian Wason New Energy Tech, a leading Chinese manufacturer of...
SKN | Avis Budget Group Explores Fresh Capital Market Opportunity as Mobility Demand Continues to Evolve
Avis Budget Group, Inc. is pursuing a new capital markets transaction as the global vehicle rental industry adapts to changing travel demand, fleet modernization,...
SKN | Viking Acquisition Corp. II: Blank-Check Vehicle Returns as SPAC Market Seeks Selective Revival
Viking Acquisition Corp. II is preparing for a capital markets entry as the SPAC sector continues to recalibrate after a prolonged downturn in blank-check...
SKN | Tarsier Pharma Ltd.: Ophthalmology Biotech Seeks Capital Markets Validation for Dry Eye Disease Pipeline
Tarsier Pharma Ltd. is moving toward a public market listing as biotech investors continue to reassess early-stage therapeutic platforms amid tightening capital conditions. The...